维普中文期刊产品整合服务
31篇 您的检索式:作者名="Sander CR"
    题名 作者 年代 出处 被引量
1中低收入国家癫痫过早死亡:国际抗癫痫联盟死亡率专业组系统评价显示文摘为了确定中低收入国家(Low-and middle-income countries,LMICs)癫痫相关的危险因素大小与过早死亡原因,专业组对来自LMICs(世界银行定义)的死亡率及癫痫相关文献报道进行系统检索,根据代表性,病例、诊断和死亡率的确证度对研究进行评估,并提取癫痫患者中的标准化死亡比(Standardized mortality ratios,SMR)和死亡率数据。研究调查了死亡的危险因素和原因。据估计,在高质量的群体研究中,癫痫患者年死亡率为19.8/1 000(9.7/1 000~45.1/1 000),加权中位SMR为2.6(1.3~7.2)。而临床队列研究显示的死亡率为7.1/1 000(1.6/1 000~25.1/1 000),加权中位SMR在男性中为5.0,女性中为4.5。在儿童和青少年、症状性癫痫或治疗依从性低的患者中发现了相对较高的SMR。群体研究显示,LMICs癫痫患者死亡的主要原因中直接归因于癫痫的平均比例死亡比(Proportional mortality ratio,PMR)为27.3%(5.0%~73.5%)。这些直接原因包括癫痫持续状态(报道的PMR为5.0%~56.5%)和癫痫猝死(Sudden unexpected death in epilepsy,SUDEP)(报道的PMR为1.0%~18.9%),与癫痫相关的间接死亡原因包括溺水、头部创伤和烧伤。LMICs癫痫患者的早亡率明显高于高收入国家。在LMICs,死亡率过高可能与患者难以获得医疗资源有关,例如发生癫痫持续状态时,以及包括溺水、头外伤和烧伤在内的可预防死因。这类过高的早亡率可以通过进行关于死亡风险的教育,提高治疗,包括抗癫痫药物治疗的可得性而大大降低。Levira F Thurman DJ Sander JW Hauser WA Hesdorffer DC Masanja H OdermattP Logroscino G Newton CR 陆璐 童馨 慕洁 2019癫痫杂志2019,5,1:2
2Nitrous oxide with propofol reduces somatosensory-evoked potential amplitude in children and adolescents显示文摘Schaney CR Sanders J Kuhn P 2005Spine2005,30,6:1
3Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals显示文摘Sander CR Pathan AA Beveridge NE 2009Am J Respir Cri Care Med2009,179,8:1
4Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials 显示文摘McShane H Pathan AA Sander CR 2005Tuberculosis ( Edinb )2005,85,12:1
5Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans 显示文摘McShane H Pathan AA Sander CR 2004Nat Med2004,10,11:1
6Recombinant modi- fied vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired antimycobacterial immunity in hu- mans显示文摘McShane H Pathan AA Sander CR 2004Nat Med2004,10,11:1
7Safety and immunogenicity of a new tuberculosis vaccine,MVA85A,in Mycobacterium tuberculosis-infected individuals显示文摘Sander CR Pathan AA Beveridge NE 2009Am J Respir Crit Care Med2009,179,8:1
8Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials 显示文摘Pathan AA Sander CR Fletcher HA 2007PLoS ONE2007,2,10:1
9Stem cell research 显示文摘Sanders RC Jr Slayton WB Cogle CR 2006Paediatr Respir Rev2006,7,2:1
10Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials 显示文摘Pathan AA Sander CR Fletcher HA 2007PLoS One2007,2,10:1
11Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans显示文摘McShane H Pathan AA Sander CR 2004Nat Med2004,10,11:1
12Common bile duct evaluation in the era of laparoscopic cholecystectomy显示文摘Voyles CR Sanders DL Hogan R 1994Am Surg1994,219,:1
13An overview of stem cell research and regulatory issues显示文摘Cogle CR Guthie SM Sanders RC 2003Mayo Clin Proc2003,78,8:1
14Boosting BCG with MVA85A:the first candidate subunit vaccine for tuberculosis in clinical trials显示文摘McShane H Pathan AA Sander CR Goonetilleke NP Fletcher HA Hill AV 2005Tuberculosis (Edinb)2005,85,12:1
15Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCGprimed and naturally acquired antimycobacterial immunity in humans显示文摘Mc Shane H Pathan AA Sander CR 2004Nat Med2004,10,11:1
16Immunisation with BCG and recombinant MVA85A induces long-lasting,polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations显示文摘Beveridge NE Price DA Casazza JP Pathan AA Sander CR Asher TE Ambrozak DR Precopio ML Scheinberg P Alder NC Roederer M Koup RA Douek DC Hill AV McShane H 2007Eur J Immunol2007,37,11:1
17Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans显示文摘Mc Shane H Pathan AA Sander CR 2004Nat Med2004,10,11:1
18Boosting BCG with MVA85A:the first candidate subunit vaccine for tuberculosis in clinical trials显示文摘Mc Shane H Pathan AA Sander CR 2005Tuberculosis(Edinb)2005,85,12:1
19Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired anfimycobacterial immunity in humans显示文摘McShane H Pathan AA Sander CR 2004Nat Med2004,10,11:1
20Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans显示文摘McShane H Pathan AA Sander CR 0,,11:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费